File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1080/030097402320318431
- Scopus: eid_2-s2.0-0036351504
- PMID: 12369656
- WOS: WOS:000177729700009
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis
Title | A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis |
---|---|
Authors | |
Keywords | Rofecoxib Cox-2 Ra Nsaid Naproxen |
Issue Date | 2002 |
Publisher | Informa Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/03009742.asp |
Citation | Scandinavian Journal of Rheumatology, 2002, v. 31 n. 4, p. 230-238 How to Cite? |
Abstract | Objective : To evaluate the efficacy and tolerability of rofecoxib 25 mg and 50 mg once daily versus placebo and naproxen 500 mg twice daily in patients with RA. Methods : Eligible patients were randomized (double-blind) to placebo (n = 289), rofecoxib 25 mg (n = 306), 50 mg (n = 286) once daily, or naproxen (n = 142) for 12 weeks. Efficacy assessments included the ACR core set, with prespecified primary endpoints: patient and investigator global assessments of disease activity, tender and swollen joint counts. Investigator-reported adverse experiences, routine laboratory and vital sign measurements were monitored. Results : Rofecoxib 25 mg, 50 mg, and naproxen provided similar treatment effects, significantly different from placebo, consistent with improvement, for all primary endpoints. Effects were evident at the earliest assessment (week 2) and sustained for 12 weeks. All treatments were generally well-tolerated. Conclusions : Rofecoxib 25 mg once daily had similar efficacy to naproxen 500 mg twice daily (a standard dose). No additional benefit was seen with 50 mg rofecoxib. |
Persistent Identifier | http://hdl.handle.net/10722/222202 |
ISSN | 2023 Impact Factor: 2.2 2023 SCImago Journal Rankings: 0.638 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Geusens, PP | - |
dc.contributor.author | Truitt, K | - |
dc.contributor.author | Sfikakis, P | - |
dc.contributor.author | Zhao, PL | - |
dc.contributor.author | DeTora, L | - |
dc.contributor.author | Shingo, S | - |
dc.contributor.author | Lau, CS | - |
dc.contributor.author | Kalla, A | - |
dc.contributor.author | Tate, G | - |
dc.date.accessioned | 2016-01-04T07:39:27Z | - |
dc.date.available | 2016-01-04T07:39:27Z | - |
dc.date.issued | 2002 | - |
dc.identifier.citation | Scandinavian Journal of Rheumatology, 2002, v. 31 n. 4, p. 230-238 | - |
dc.identifier.issn | 0300-9742 | - |
dc.identifier.uri | http://hdl.handle.net/10722/222202 | - |
dc.description.abstract | Objective : To evaluate the efficacy and tolerability of rofecoxib 25 mg and 50 mg once daily versus placebo and naproxen 500 mg twice daily in patients with RA. Methods : Eligible patients were randomized (double-blind) to placebo (n = 289), rofecoxib 25 mg (n = 306), 50 mg (n = 286) once daily, or naproxen (n = 142) for 12 weeks. Efficacy assessments included the ACR core set, with prespecified primary endpoints: patient and investigator global assessments of disease activity, tender and swollen joint counts. Investigator-reported adverse experiences, routine laboratory and vital sign measurements were monitored. Results : Rofecoxib 25 mg, 50 mg, and naproxen provided similar treatment effects, significantly different from placebo, consistent with improvement, for all primary endpoints. Effects were evident at the earliest assessment (week 2) and sustained for 12 weeks. All treatments were generally well-tolerated. Conclusions : Rofecoxib 25 mg once daily had similar efficacy to naproxen 500 mg twice daily (a standard dose). No additional benefit was seen with 50 mg rofecoxib. | - |
dc.language | eng | - |
dc.publisher | Informa Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/03009742.asp | - |
dc.relation.ispartof | Scandinavian Journal of Rheumatology | - |
dc.rights | Scandinavian Journal of Rheumatology. Copyright © Informa Healthcare. | - |
dc.subject | Rofecoxib | - |
dc.subject | Cox-2 | - |
dc.subject | Ra | - |
dc.subject | Nsaid | - |
dc.subject | Naproxen | - |
dc.title | A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis | - |
dc.type | Article | - |
dc.identifier.email | Lau, CS: cslau@hku.hk | - |
dc.identifier.authority | Lau, CS=rp01348 | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1080/030097402320318431 | - |
dc.identifier.pmid | 12369656 | - |
dc.identifier.scopus | eid_2-s2.0-0036351504 | - |
dc.identifier.hkuros | 84504 | - |
dc.identifier.volume | 31 | - |
dc.identifier.issue | 4 | - |
dc.identifier.spage | 230 | - |
dc.identifier.epage | 238 | - |
dc.identifier.isi | WOS:000177729700009 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 0300-9742 | - |